Yes I do!! "DEAD MONEY"
Did I miss something?
Oh, I just remembered: "PATHETIC".

Read the optimistic statements from a multitude of doctors and researchers, who are in the trenches, treating patients. They weigh heavily on the probability scale. Do your own DD!!

Yes it can! You've provide the proof EVERY day!
Hmm..., I see a significant escalation of firepower, unfortunately, still not persuasive!

I guess you haven't been reading the many posts discussing developments in the various indications!
Twice in an hour! Hundreds of times in the last few months. Still not persuasive!

Evidently not in your mind! On the other hand, most of us think that the "DEAD MONEY" meme is a bit overdone! (LOL), in fact you yourself said that you've been posting it for months! And you have!!!... For months!! ... LIke De Gaulle said, reports of my demise are premature! (LOL)
That's what they're supposed to do! You know, to keep investors informed. It's sort of like.... INFORMATION, it's what you and "horsesho" have been complaining you don't get enough, and now it's too much?

All six hundred with "DEEP POCKETS" ? Surely you jest! (LOL)
And here's poor little Pluristem, with the best technology, with a P3 for an indication with a huge patient pool and many signals of probable success!!!
Yes they do! It's called patents. Look it up, it means "exclusive"!!!
No, it's a careful calculation of probabilities, looks good to me, not to you, feel free to sell or short, Good Luck!

So will Pluristem!!! AND BTW, BEFORE Apple had a "thriving business" they didn't, then they did! That's the way it works!

I think that's what IBM said to Microsoft and Apple a while back. Today Apple could buy IBM outright with what is pocket change (Apple 6x the size of IBM).

If you have a patented product that is better than everybody else's, OR fills a gap that nobody is addressing, big money is not the determinant. A big advertising budget will not deter a patient from insisting on the medicine that will prevent amputation (i.e. PLX-PAD).

The approach (using charts) is one way to do it, and if it works for you, fine!

But wouldn't you say that the alternative approach, one that is based on the probability that the upside is massive (if let's say we get an approval for CLI), if one believes that the probability of that is pretty high (as I do) then, in that case, accumulating as much as as you can NOW, and not worrying about short term fluctuations, is equally reasonable?

And, if it does work out, wouldn't you end up with more shares at a lower price, and a greater ROI? That's my working hypothesis. It's a gamble, but the odds are pretty good (my personal opinion!). No way you can remove all uncertainty in investing, not even with charts.

Oh no!! My biggest fear is becoming a reality. Pluristem vanquished by horseradish!! And why didn't hopester's charts warn us about this? Clearly an early warning system that is insensitive to HORSRADISH is inadaquete.

Who could have guessed that lurking in the deep fog, we have..... HORSERADISH, ready to pounce!

I think all our competitors (you know the ones with "deep pockets") have also been blindsided! Is Novartis prepared for the HORSERADISH wars? Does management ever eat horseradish? How could they have missed this threat? How do we invest in the horseradish revolution, we all want to know.

BTW, is it applied topically, by IV, pills, or do you just use it as condiment on your mashed potatoes???

Let's hope this is not the END of PSTI!!!

I'll say!
I'm looking forward to your signal to buy, BEFORE the pps goes up!
You see, I have an open mind.

Strange that you would say that, if anyone compares your ... ahem ... theses, what jumps out is the vast superiority of Spideyboy's knowledge, his understanding of the domain, the specificity of his analysis with respect to Pluristem, not to mention his civility, in fact I would say it wouldn't even be possible to compare (apples to ...), to put it succinctly, you and Spideyboy.... incommensurable!!!

Your post speaks for itself!!!

Spideyboy, thanks for reiterating and expanding on the points I've been making this morning. The superiority of PLX-R18 is clear and obvious (if you look at the publicly available information). I hope the details and the gravitas you added will be persuasive (but I doubt it!)

I would! At least on my understanding of the meaning of "dissent".

Less than a year, and thank you, I'm very pleased so far. All news has been very positive, and my expectations are for a huge ROI.
You might want to do something about that, an early cure is the best cure (I have heard that Pluristem is working on PLX-LMAO, there's always hope).

hope(less)ster warned against putting on blinders. I think that your statement is an eminently fitting example of blinders, on top of distorting filters. Pay attention to "hope"'s advice, I do (of course, after turning it upside down and 180 degrees).
Only if you invested all of your retirement money, and your kids college fund, and even then, I'd only be VERY afraid (only 1x, maybe divided by 2).

I'm not able to interpret that (and I do have a good command of English) For me the history of Pluristem started when I invested less than a year ago ("Umpteen" does seem like a LONG time).

I'm still very pleased and looking forward for PSTI's POTENTIAL to be fulfilled (in less than "Umpteen" but I can't say how much less for the obvious reason, I'll calculate the approximate time as soon as I find out the definition of "Umpteen" ).
OMG, it's contagious! (LOL, but not my A. off!)

No, he's not! I'll be concerned when the competition comes up with something even close to PLX-R18 in its broad support of reconstituting all cells lines after any kind of radiation damage. Only PLX-R18 can do that!

The only competition to PLX-PAD in CLI is revasc. surgery, not much of a competing therapy.

It's all about the POTENTIAL!!

There will be, call it POTENTIAL! As far as "crushing" anything, it sure as heck not going to be some one dimensional drug from Novartis, not even close to the responsiveness and multiple actions of PLX-R18. And then, there's PLX-PAD, the POTENTIAL is tremendous!!

This seems to be the BIG GUN of the psti is "DEAD MONEY" crowd. Pretty meager in my view.

The price IS $1.29 AND if you believe that there's NO POTENTIAL, then the obvious action item is to sell if you own and do nothing if you don't!

Me, I'm accumulating!!

BTW, POTENTIAL is the ONLY thing to justify buying a pre-commercial biotech!

Please read my post #13896 this AM. A VERY STRONG dissenting opinion!

No need for any fear. I would also recommend the article by Zach Hartman, PhD. Here's the relevant exerpt:

"it should be emphasized that (Novartis's) eltrombopag is not likely to be a strong competitor (to Pluristem), since there is a lot more that needs to be done to repair the damage done by radiation."

I hope your fears have been allayed!

if not read my additional comments:

I see Novartis' interest as a POSITIVE! It shows that the target indications (multiple) represent a huge value. Pluristem will be there first and with a better product!

If you're still afraid do some research on PLX-R18 and the realization that a live cell, responding to the distress signals coming from the very cells that are in trouble, will be a more effective treatment option, your fears will subside. In fact I would say that PLX-R18 is a very good treatment for fears about BIG Novartis.

Hi Mikems, thanks for the link.

It's always good to see references to Pluristem. I think our "fame" will increase when PLX-PAD is approved for CLI, and PLX-R18 for radiation sickness (in many areas, not just military).

I don't even know how respond to that kind of statement. Why would anybody invest in biotech is he rejects the most fundamental notion of biotech investing. This is NOT a divident stock, you invest in Pluristem for the POTENTIAL. There's no other reason!

It's hard to see that (must your charts are helping you, LOL)!

You missed this part of the article:

"it should be emphasized that eltrombopag is not likely to be a strong competitor (to Pluristem), since there is a lot more that needs to be done to repair the damage done by radiation."

The author of the article, Zach Hartman is PhD (biochemistry and molecular biology) and a very decent and intelligent observer of the biotech scene. When you leave out relevant information from the article, you undermine your argument (among other things).

An additional note: I see Novartis' interest as a POSITIVE! It shows that the target indications (multiple) represent a huge value. Pluristem will be there first and with a better product! How can I know this WITHOUT charts? Easy, look at the available data (as opposed to black magic).

"Eich"s prediction is based on ZERO!
How could he possibly "know"???

ALL indications are for a huge success for Pluristem!
$20 is about 2.3 billion MC, easily achieved by a company
with a potential for a multi-billion drug (for CLI for example)

Yes you have!!!

I would put it differently (as made it very clear!)

I DO NOT THINK T.A. IS WORTH BOTHERING WITH!
I THINK IT'S JUNK SCIENCE!
I THINK IT'S AN UTTERLY USELESS AND INAPPROPRIATE
AND GENERALLY WEAK TOOL, AND LESS THAN WEAK WHEN IT
COMES TO THIS COMPANY.

I'm NOT "ignoring" it, I'm dismissing it!!!!!!!!!

Major difference!!!

The economy is influenced by many directly known factors, such as economic policy, trade policy, Fed bank policy, and hundreds of others. Much of this is publicly known and followed/analysed by thousands of economists and corporations.

Compare this to a small biotech, where much of the important information is being gathered by a few dozen researchers and doctors. A small Israeli company in Haifa does not have the "market"s attention, so it can hum along with barely anybody noticing it. UNTIL the BIG news: Pluristem declares success in P3 for CLI!
At that point Pluristem explodes, and the general market will most likely still not be aware of it.

For Pluristem, the leading indicators are the bits and pieces of data that we get in dribs and drabs, and only a handful of interested investors are aware of it. That's why the market at large has zero relevance here, they don't know PSTI even exists, but they will (those that are interested in biotech)!!

Note that if we pop up to 3 billion dollars (a 20 bagger from here) it will have a big impact on our finances (mine in any case), but Pluristem will still be a tiny micro cap most will never have heard about.

Thanks Saraceno! EOM

That's a REALLY strange response to a post
in which I made it clear that I have zero regard for the "market"
as a determinant of the (MY) expected valuation for THIS company.

The "market" in not some mystical entity with deep knowledge and
insight into the potential value and the science that will define Pluristem's
future. Once more: the market is a lagging indicator!!!

The "market" says the Apple is very valuable. The "market" did NOT
tell anyone that it will be a massive success twenty years ago.

So it's simple: buy low (now), IFF you think Pluristem is on the verge
of revolutionizing the treatment for CLI, etc. The "market" and charts
have no insight in this regard, BUT the scientists I referred to in my
previous post, THEY DO. I'm formulating my investment approach
by paying a lot of attention to what they're saying.
This particular long is adducing each piece
of "good news" (data/information) to understant the direction of Pluristem,
and using that knowledge to assess our progress toward approvals
and actually making the therapy available to patients.
That's the "trend" I'm interested in.

Right this moment (1:42PM local time) the market is telling me
that the price of a share of PSTI is $1.29. The only implication of
that is that I can calculate the CURRENT value of my investment.
NOTHING beyond that!

Hmmm.. let me think about that.

OK, I thought about it, you're are right sir!!!

Boy, isn't that the truth (but, all's well that ends well)
I do believe that Dr.Kleinhaus' point is real cause for optimism:

"The optimal dosing regimen in the Phase II study in IC
is the same regimen used in the Phase III CLI trial and
bodes very well for the pivotal study."

I do believe that we have a pretty good indication of the likelihood
of a positive outcome for CLI p3.

Me neither, I invested here before I was even aware of the DES indication.
Glad that Vascepa solved your problems. I would imagine that
it might not work for other patients where Vocl. might be useful.

Aurinia management must have some notion of the usefulness
of the Vocl/DES formulation, even in the context of currently available
remedies. The fact that Restasis is still on the market is at the very
least a good hint that there's an ongoing need, AND there are indications
that Vocl. is better than Restasis.

From Dr. Karine Kleinhaus' Blog, Jun 19 2018

(I guess the "market" does not read Dr. Kleinhaus' blog!)


Pluristem just announced top-line results from a Phase II study of PLX-PAD in the treatment of intermittent claudication, a less severe form of peripheral artery disease.

The Phase II study showed that PLX-PAD cells reduced the incidence of revascularization and improved patients’ mobility. In those who received the optimal PLX-PAD regimen, at 52 weeks the improvement in maximal walking distance from baseline was 42% better (p=.043) versus the placebo group.

The need for vascular surgery was eliminated through week 65 in patients who received the optimal dosing regimen.

This was a fairly large study, with 172 patients treated in 28 sites in the U.S., Germany, South Korea, and Israel.
Efficacy data validated the key elements of the protocol for the ongoing multinational Phase III study in CLI including the number of cells per dose, dual dosing, and sourcing each of the two doses from different placentas.

The optimal dosing regimen in the Phase II study in IC is the same regimen used in the Phase III CLI trial and bodes very well for the pivotal study.

Regulators are eager for an innovative new therapy to address this severe unmet need and have selected PLX-PAD for rapid regulatory pathways in the U.S., Europe and Japan. The U.S. FDA has also approved the use of PLX-PAD in CLI through its Expanded Access Program, for patients who do not qualify for Pluristem’s Phase III CLI study. When 12 months of data are available on the first 50% of patients in this trial, European regulators may allow for interim results to be evaluated in support of early conditional marketing approval under the EMA’s Conditional Marketing Authorization program.

No, there's "Eich" and then there's "horsesho", and ... oh yeah, THE MARKET (LOL).

What the market is saying is "the PPS is 1.25", TODAY" !!!!

Nothing else! Because it ("the market") doesn't know!
Because the market is not EFFICIENT, it's always lagging,
it doesn't know anything about the sort of data coming from
scientists and doctors like:

Dr. Akihiro Inano, Fukushima University. He says:
“we were impressed by PLX-R18’s ability
to increase survival by mitigating the damage of high levels
of radiation on these organ systems"

Prof. Reuven Or, Bone Marrow Transplantation and Cancer Immunotherapy Research Center:
a new method that would prolong survival and improve quality of life for these patients is on the horizon.
Five years ago, Or tested a new methodology for assisting three patients who underwent failed bone-marrow transplants, injecting a simple shot of placenta-derived cells, into the thigh of each patient. The results were that their bodies started creating new blood cells, repopulating their blood system and improving their health.
“It worked in all three cases,” said Or

U.S. National Institutes of Health,
Prof. Gorodetsky at Hadassah,
researchers at the Charité University Hospital in Berlin,
and other prominent research institutions have shown:
" that PLX-R18 cells secrete a range of specific proteins that salvage and trigger the regeneration of bone marrow hematopoietic (blood-producing) cells. In this way, they efficiently support the indirect recovery and regeneration of the blood system."

etc.,etc.,...... There's a lot more!!!

To get your investment advise from the "market" is like asking
a bank robber to give you a lecture on banking principles.
I think you'll get a very limited perspective! (LOL)

My investment in Pluristem is predicated on the reasonable
calculation of probabilities that these folks know a lot more than
a bunch a day traders and shorts! When the "market" tells you what
to do, the train has left the station, the ship has sailed....
too late to get in when it's low, 'cause by then it will be high!

I would guess it will take Oyster longer than that.
The fact that it's a systemic medication VS Vocl. which is topical (for DES), they
might have a bigger hurdle to get it past the FDA, and we have yet to see
the side effects profile. All speculation of course.

Makes you wonder why some of the most
competent doctors and thought leaders are using
Pluristem's product on their patients. Maybe they know something
the "market" doesn't know.
It's not! See previous paragraph.
Hmmm...Doesn't quite work!
I would leave the poetry to Mikey.

I have an even better one (or more):

1. Tomorrow morning an announcement of a contract for PLX-R18
or
2. Results for CLI so positive that they abort clinical trial and declare victory
(could happen, or we may have to wait a few months)
or
3. Major parthership, with money up front

etc. ...

Charting has zero value for a small biotech awaiting news that
could change the landscape of medical science precipitously.

But then it's to late:
Buy low, sell high! Requires that you buy low.

The application of the "average down" technique has to
take into account the potential of the company, and the
probability that it gets there! Sears (brick and mortar retail)
is a dying industry, MSCs as medicine is the future, bad
comparison.

Not very credible!

The statement does have the form of the propositional logic:
if x then y. As stated by "Eich", it doesn't seem to have
any possible interpretation that makes sense to me.

LOL! The real-estate Pluristem is sitting on is worth more than that!

Our valuation today is about 140 million dollars.

The market for CLI is very likely multiple billions.
Think about the effect on Pluristem's MC. We only
need to get to 2.8 billion dollars for a 20 bagger.

Eminently possible! Even if there's some dilution
along the way, and some profit sharing with partners.

.. and even lower, as low as 1.25!!
That's the idea! Buy low, sell high!

The lower your average the more ROI when Pluristem
is in the twenties. If anyone thinks that that's unrealistic,
think about the millions of people in the Eu. and the US who
desperately need help for CLI (not to mention the rest of the world,
AND other indications for PLX-PAD).